Search - tctmd.com

Displaying 101 - 120 of 140

Sort: Relevancy | Date

News Daily News

LAA Closure With Amplatzer Appears Safe, Effective in A-fib Patients

Yael L. Maxwell

November 06, 2014

Presentation TCT 2014

Anticoagulation After LAA Closure in Anticoagulation Eligible and Ineligible Patients

Presenter: Ted E. Feldman, Saibal Kar, Zoltan G. Turi, Jacqueline Saw

September 16, 2014

Presentation TCT 2014

TCT 171: Avoidance of Major Bleeding with WATCHMAN Left Atrial Appendage Closure Compared with Long-term Oral Anticoagulation: A Pooled Analysis of Randomized Trials

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Matthew J. Price

September 15, 2014

Presentation TCT 2014

LARIAT Experience in Patients Contraindicated to Anticoagulation

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Sameer Gafoor

September 15, 2014

Presentation TCT 2014

Yes, It Is a Good Option for Most Anticoagulation Eligible Patients

Presenter: Saibal Kar

September 15, 2014

Presentation TCT 2014

No, It Should Be Limited to Patients with Absolute Anticoagulation Contraindications

Presenter: Jai-Wun Park

September 15, 2014

News Daily News

PREVAIL Published: Watchman, Warfarin Show Comparable Stroke Protection in A-fib

July 03, 2014

News Conference News EuroPCR 2014

Benefit of LAA Closure Becomes Most Evident After 1 Year

Caitlin E. Cox

May 23, 2014

Presentation EuroPCR 2014

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Presenter: Jos? Ram?n L?pez-M?nguez

May 21, 2014

Presentation TCT 2013

Clinical Trial Alternatives for New LAA Occlusion Devices: For High-Risk AF Patients Who Are Tolerant to Anticoagulation or Poor Anticoagulation Candidates Due to Bleeding Risks...

Presenter: Brian Whisenant

October 30, 2013

Presentation TCT 2013

Long term follow up of 134 patients with non valvular atrial fibrillation and contraindications to oral anticoagulation therapy, treated with the Ampatzer Cardiac Plug Device for LAA

Presenter: Miroslava Stolcova

October 29, 2013

Presentation TCT 2013

Stroke, Bleeding and Risk Scores in Atrial Fibrillation (with and without Anticoagulation)

Presenter: Stefan Bertog

October 27, 2013

Presentation TCT 2013

Current Use Patterns of Chronic Oral Anticoagulation: Penetration, Agent Selection, Complications, and Defining the Anticoagulant Ineligible Patient

Presenter: Michael Ezekowitz

October 27, 2013

News Conference News ESC 2013

Pooled Trial, Registry Data Support Watchman for Stroke Prevention in A-fib

Yael L. Maxwell

September 02, 2013

News Daily News

Risk Factors for Thrombus Formation on Cardiac Plug in A-fib Patients Identified

Yael L. Maxwell

June 28, 2013

Presentation TVT 2013

Who Is Really Contraindicated for Oral Anticoagulation Therapy? Are There Absolute Guidelines?

Presenter: Steven Goldberg

June 15, 2013

Presentation TVT 2013

LAA Closure for the Anticoagulation Intolerant Patient: Data and Common Sense

Presenter: Matthew Price

June 15, 2013

Presentation TVT 2013

Is Triple Therapy a Triple Threat for Patients? DAPT and Chronic Anticoagulation

Presenter: Ted Feldman

June 15, 2013

Presentation TVT 2013

"New" Anticoagulation Options for A-fib: Beyond Warfarin

Presenter: Michael Ezekowitz

June 15, 2013

Presentation

Percutaneous LAA Closure with the Amplatzer Cardiac Plug in Patients with Nonvalvular A-fib and Contraindications for Anticoagulation Therapy

Presenter: M. Urena

May 28, 2013

Advertisement

LAA Closure With Amplatzer Appears Safe, Effective in A-fib Patients

Anticoagulation After LAA Closure in Anticoagulation Eligible and Ineligible Patients

TCT 171: Avoidance of Major Bleeding with WATCHMAN Left Atrial Appendage Closure Compared with Long-term Oral Anticoagulation: A Pooled Analysis of Randomized Trials

LARIAT Experience in Patients Contraindicated to Anticoagulation

Yes, It Is a Good Option for Most Anticoagulation Eligible Patients

No, It Should Be Limited to Patients with Absolute Anticoagulation Contraindications

PREVAIL Published: Watchman, Warfarin Show Comparable Stroke Protection in A-fib

Benefit of LAA Closure Becomes Most Evident After 1 Year

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Clinical Trial Alternatives for New LAA Occlusion Devices: For High-Risk AF Patients Who Are Tolerant to Anticoagulation or Poor Anticoagulation Candidates Due to Bleeding Risks...

Long term follow up of 134 patients with non valvular atrial fibrillation and contraindications to oral anticoagulation therapy, treated with the Ampatzer Cardiac Plug Device for LAA

Stroke, Bleeding and Risk Scores in Atrial Fibrillation (with and without Anticoagulation)

Current Use Patterns of Chronic Oral Anticoagulation: Penetration, Agent Selection, Complications, and Defining the Anticoagulant Ineligible Patient

Pooled Trial, Registry Data Support Watchman for Stroke Prevention in A-fib

Risk Factors for Thrombus Formation on Cardiac Plug in A-fib Patients Identified

Who Is Really Contraindicated for Oral Anticoagulation Therapy? Are There Absolute Guidelines?

LAA Closure for the Anticoagulation Intolerant Patient: Data and Common Sense

Is Triple Therapy a Triple Threat for Patients? DAPT and Chronic Anticoagulation

"New" Anticoagulation Options for A-fib: Beyond Warfarin

Percutaneous LAA Closure with the Amplatzer Cardiac Plug in Patients with Nonvalvular A-fib and Contraindications for Anticoagulation Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content